Compassionate Use and Expanded Access for Tigilanol Tiglate: What Patients Need to Know
Expanded access programmes offer a potential pathway for cancer patients to receive tigilanol tiglate outside clinical trials — here is how the regulatory process works.
What Is Compassionate Use?
For patients with serious or life-threatening conditions who have exhausted approved treatment options, regulatory agencies provide pathways known as expanded access or compassionate use. These mechanisms allow physicians to request investigational drugs — including tigilanol tiglate (EBC-46) — outside the formal clinical trial framework. [1]
In the United States, the FDA's expanded access programme encompasses three tiers: individual patient access, intermediate-size population access, and widespread treatment use. Each tier carries different procedural requirements, but all share the same core eligibility criterion: the patient must have a serious condition with no comparable or satisfactory alternative therapy available. [2]
Tigilanol Tiglate's Regulatory Position
Tigilanol tiglate received FDA approval in November 2020 under the trade name Stelfonta for veterinary use — specifically for intratumoral treatment of non-metastatic canine mast cell tumours. [3] That approval established a safety data foundation and regulatory precedent that now supports the compound's progression into human oncology development.
QBiotics Group is actively developing tigilanol tiglate for human solid tumour indications. The compound's mechanism — PKC-mediated tumour necrosis, vascular disruption, and local immune activation following intratumoral injection — is highly relevant to multiple solid tumour types. [4] Expanded access in this context applies to patients whose oncologist determines that potential benefit outweighs the investigational risks, pending a regulatory agreement.
The FDA Expanded Access Process
For individual patients, the process begins with the treating physician. The oncologist must first contact QBiotics to request access to tigilanol tiglate under an expanded access Investigational New Drug (IND) application. If QBiotics agrees to provide the drug, the physician submits Form FDA 3926 — a process the agency has streamlined to respond to most emergency requests within 24 hours. [5]
Required documentation includes a description of the patient's condition and prior treatments, the proposed treatment protocol, the expected risks and benefits, and the rationale for believing tigilanol tiglate may provide clinical benefit. Institutional Review Board (IRB) oversight is required, though emergency waivers exist for time-critical situations.
The European Compassionate Use Framework
In Europe, the EMA's compassionate use framework operates under Article 83 of Regulation (EC) No 726/2004. It allows individual member states to make investigational medicinal products available on a national basis while marketing authorisation is pending, provided the product is under evaluation or a relevant clinical trial is ongoing. [6]
Given tigilanol tiglate's active human oncology development and its existing veterinary approval in Europe under the Stelfonta EPAR, several member states may be positioned to establish national compassionate use programmes for specific patient populations. Patients and clinicians should monitor both QBiotics' communications and their national medicines agencies for updates.
What Patients Should Do
Patients interested in tigilanol tiglate should discuss the compound with their oncologist. Peer-reviewed evidence is accessible via PubMed [7] and active trials are searchable at ClinicalTrials.gov. [8] Eligibility for expanded access depends ultimately on the treating physician's clinical judgement and QBiotics' capacity to support requests.
For clinicians, QBiotics' website is the primary point of contact. [9] QIMR Berghofer has also been a key research partner and may be able to direct clinicians toward trial eligibility information or compassionate use contacts. [10]
Why Regulatory Momentum Matters
Compassionate use frameworks exist because the conventional approval pipeline — while rigorous — cannot serve every patient today. For tigilanol tiglate, which has demonstrated striking results in one approved species and is actively progressing through human trials, [11] the case for expanded access consideration grows stronger with each positive dataset. The regulatory infrastructure is in place; what drives activation is clinical demand, programme capacity, and accumulating safety evidence — all of which are moving in a consistent direction.
References
- FDA Expanded Access (Compassionate Use) overview. View source ↗
- FDA Expanded Access — eligibility and process. View source ↗
- FDA approves Stelfonta for canine mast cell tumours. View source ↗
- QBiotics Group — tigilanol tiglate development programme. View source ↗
- FDA Form 3926 and individual patient expanded access IND. View source ↗
- EMA — Stelfonta European Public Assessment Report. View source ↗
- Boyle GM et al. (2014). Intratumoural injection of EBC-46. PLOS ONE. View source ↗
- ClinicalTrials.gov — active tigilanol tiglate trials. View source ↗
- QBiotics Group. View source ↗
- QIMR Berghofer Medical Research Institute. View source ↗
- Panizza BJ et al. (2019). Phase I dose-escalation in head and neck squamous cell carcinoma. Head & Neck. View source ↗
